openPR Logo
Press release

Survanta in the Treatment of RDS in NICU Patients

07-08-2011 10:07 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ONY, Inc.

Infasurf

Infasurf

FOR IMMEDIATE RELEASE
New York, U.S:Survanta (Beractant) is widely used in the treatment of respiratory distress syndrome (RDS) in premature infants. Made from animal lung protein, Survanta keeps the lungs from collapsing by reducing the surface tension of fluids inside the lungs. Introduced in 1991, Survanta has treated more than 800,000 infants, with more than one million doses administered.

RDS is most common in premature infants who are born approximately six weeks before their due date. Infants who experience respiratory distress lack sufficient amounts of surfactant, the liquid that coats the inside of the lungs. Babies usually don’t start producing surfactant until a few weeks before they are born. Without enough surfactant, the lungs collapse and premature infants have to work hard to breathe. By reducing the surface tension of fluids inside the lungs, Survanta prevents the lungs from collapsing in infants with RDS. Infants who have RDS display symptoms of respiratory distress at birth, or in the hours immediately following birth. Typical symptoms of respiratory distress in infants include:

• Shallow, rapid breathing
• Noticeable pulling in of the chest between the ribs with each breath
• Grunting
• Flaring the nostrils

Survanta should be administered to infants who are at risk of developing RDS, or who show signs of surfactant deficiency, minutes or hours after birth. Survanta must be administered in a neonatal intensive care unit (NICU), a specialized setting for premature babies or newborns who need special care. A NICU is sometimes called a newborn intensive care, or an intensive care nursery. Babies who need to go to the NICU are often admitted within the first 24 hours after birth. Babies may be sent to the NICU if they are born prematurely, or if they have difficulties within the first few days of birth. The severity of the illness will dictate how long a baby will stay in the NICU.

Newborns who are admitted to the NICU and given Survanta will require very specialized care. As a parent, it’s important to talk with your doctor regarding any special instructions for your baby once he or she is released from the NICU, including restrictions on feeding or other medications after your baby has been treated with Survanta. It’s also important to watch for any side effects while Survanta is being administered. Survanta should only be used in a highly supervised clinical setting by neonatal specialists who are experts in the care of premature infants.

For further enquires related to ONY, Inc. and Infasurf, please free to email at info@onyinc.com or visit www.infasurf.com now.

Infasurf is a pure lung surfactant that helps in improving the breathing process of the new-born patient suffering from RDS. Survanta (Beractant) is widely used in the treatment of respiratory distress syndrome (RDS) in premature infants.

ONY, Inc.
1576 Sweet Home Rd.
Amherst, NY 14228
Tel: (716) 636-9096
Toll-free: (877) 274-4469
Monday to Friday, 9 a.m. to 5 p.m. Eastern, excluding holidays

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Survanta in the Treatment of RDS in NICU Patients here

News-ID: 182747 • Views: 1934

More Releases from ONY, Inc.

Respiratory Distress in Premature Infants
FOR IMMEDIATE RELEASE New York, NY:Respiratory distress syndrome (RDS) is a breathing condition common in premature infants whose lungs have not fully developed yet. The earlier the birth in gestational time, the more prone the infant is to RDS and the more severe it is likely to be. Fully developed lungs are coated with a naturally occurring slippery substance called surfactant. Surfactant lines the air sacs in the lungs and reduces surface

More Releases for Survanta

Respiratory Distress Syndrome Market Analysis and Forecast 2018-2026 | ONY Biote …
"The Latest Research Report Respiratory Distress Syndrome Market - Global Industry Trend Analysis 2013 to 2017 and Forecast 2018-2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Respiratory distress syndrome is a lung disorder of neonates caused by a deficiency of surfactants. It affects premature infants with symptoms of collapsed lungs and breathing difficulty. Other symptoms include nasal flaring, use of accessory
The Role of Neonatal Nurse Practitioners in the Treatment of Infant Respiratory …
FOR IMMEDIATE RELEASE New York, U.S.:Newborns who are diagnosed with infant respiratory distress syndrome (RDS) are often cared for by neonatal nurse practitioners in a neonatal intensive care unit (NICU). Infant respiratory distress syndrome is characterized by a lack of surfactant in the lungs. Surfactant is a naturally occurring substance that coats the lungs and helps them to function properly. Infants who are born prematurely -- that is, born at least
Treating Infant Respiratory Distress Disorders with Pulmonary Surfactants
FOR IMMEDIATE RELEASE New York, U.S.:Infants who experience respiratory distress disorders are commonly treated with pulmonary surfactants. Respiratory distress syndrome (RDS) is a condition in which the lungs are not fully developed and the infant has trouble breathing on his or her own. This is due to insufficient amounts of surfactant, which is a naturally occurring substance that coats the lungs and allows them to function properly. Infants who are born